Literature DB >> 1601753

The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus.

G Seibert1, D Isert, N Klesel, M Limbert, A Markus, E Schrinner.   

Abstract

Cefpirome, cefoperazone and ceftazidime were tested for their in-vitro activity against Enterococcus faecalis and methicillin-resistant Staphylococcus aureus (MRSA) isolates. Cefpirome was the most active cephalosporin followed by cefoperazone. Ceftazidime had only very limited activity against these strains. In experiments with cefpirome/vancomycin and cefoperazone/vancomycin combinations, synergy was detected against most MRSA strains and some enterococci. Antagonism did not occur.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1601753     DOI： 10.1093/jac/29.suppl_a.25

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  8 in total

1.  Antibiotics: Synergistic MRSA combinations.

Authors:  Karen Bush
Journal:  Nat Chem Biol       Date:  2015-11       Impact factor: 15.040

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

3.  Vancomycin and oxacillin synergy for methicillin-resistant staphylococci.

Authors:  B E Domaracki; A M Evans; R A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin.

Authors:  N Aritaka; H Hanaki; L Cui; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.

Authors:  Kimberly D Leuthner; Celine Vidaillac; Chrissy M Cheung; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

6.  In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains.

Authors:  S Rochon-Edouard; M Pestel-Caron; J F Lemeland; F Caron
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Bactericidal activity of cefpirome (HR 810) against 513 gram-negative bacteria isolated from blood of septicemic patients.

Authors:  M G Bergeron; M Bernier
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

8.  CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.

Authors:  Steven Y C Tong; Jane Nelson; David L Paterson; Vance G Fowler; Benjamin P Howden; Allen C Cheng; Mark Chatfield; Jeffrey Lipman; Sebastian Van Hal; Matthew O'Sullivan; James O Robinson; Dafna Yahav; David Lye; Joshua S Davis
Journal:  Trials       Date:  2016-03-31       Impact factor: 2.279
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.